Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors

Journal of Clinical Oncology

Volumn 17, Issue 2, 1999, Pages 685-696

  Drengler, Ronald L ^a   Kuhn, John G ^a   Schaaf, Larry J ^a   Rodriguez, Gladys I ^a   Villalona Calero, Miguel A ^a   Hammond, Lisa A ^a   Stephenson Jr , Joseph A ^a   Hodges, Stephanie ^a   Kraynak, Maura A ^a   Staton, Brian A ^a   Elfring, Gary L ^a   Locker, Paula K ^a   Miller, Langdon L ^a   Von Hoff, Daniel D ^a   Rothenberg, Mace L ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRINOTECAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; FEMALE; FRUIT JUICE; HUMAN; LIVER METASTASIS; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0033053185     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.2.685     Document Type: Article

References (26)

1. Rothenberg ML: CPT-11: An original spectrum of clinical activity. Semin Oncol 23:21-26, 1996 (suppl 3)
2. Von Hoff DD, Rothenberg ML, Pitot HC, et al: Irinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer: Overall results of FDA-reviewed pivotal US clinical trials. Proc Am Soc Clin Oncol 16:228a, 1997 (abstr 803)
3. Kawato Y, Furuta T, Aonuma M, et al: Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 28:192-198, 1991
4. Houghton PJ, Cheshire PJ, Hallman JD II, et al: Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36:393-403, 1995
5. Thompson J, Zamboni WC, Cheshire PJ, et al: Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res 3:423-432, 1997
6. Saltz L, Early E, Kelsen D, et al: Phase I study of chronic daily low-dose irinotecan (CPT-11). Proc Am Soc Clin Oncol 16:200a, 1997 (abstr 701)
7. Herben V, Schellens J, Swart M, et al: Phase I and pharmacokinetic study of irinotecan (CPT-11) with a prolonged (14D) infusion schedule. Proc Am Soc Clin Oncol 16:201a, 1997 (abstr 705)
8. Takasuna K, Hagiwara T, Hirohashi M, et al: Involvement of beta-elucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56:3752-3757, 1996
9. Thompson J, Zamboni WC, Cheshire PJ, et al: Efficacy of oral irinotecan against neuroblastoma xenografts. Anticancer Drugs 8:313-322, 1997
10. Ruwart MJ, Wilkinson KF, Rush BD, et al: Preliminary evaluation of the oral bioavailability of U-101440E (CPT-11) from bulk drug and solution in beagle dogs. Upjohn Technical Report 7256-94-097, 1994
11. Ratke CC, Stewart NL, Stout CL, et al: A fourteen-day oral and intravenous dose toxicokinetic study in female beagle dogs. Upjohn Technical Report 7227-94, 1994
12. Yancey MF, Shobe EM: HPLC quantitation of total U-101440 (CPT-11, irinotecan) and U-101503 (SN-38) in dog plasma at concentrations of 1 to 4000 ng/mL using protein precipitation and HPLC with fluorescence detection. Upjohn Technical Report 7256/101440-102.1, 1994
13. Gibalidi M: Biopharmaceutics and Clinical Pharmacokinetics (ed 3). Philadelphia, PA, Lea & Febiger, 1984
14. Chabot GG, Abigerges D, Catimel G, et al: Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 6:141-151, 1995
15. Rothenberg ML: Topoisomerase I inhibitors: Review and update. Ann Oncol 8:837-855, 1997
16. Eng W-K, Faucette L, Johnson RK, et al: Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 34:755-760, 1988
17. Chen AY, Liu LF: Mechanisms of resistance to topoisomerase inhibitors. Cancer Treat Res 73:263-281, 1994
18. Gerrits CJH, de Jonge MJA, Schellens JHM, et al: Topoisomerase I inhibitors: The relevance of prolonged exposure for present clinical development. Br J Cancer 76:952-962, 1997
19. Liu G, Franssen E, Fitch MI, et al: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110-115, 1997
20. Rothenberg ML, Kuhn JG, Burris HA III, et al: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194-2204, 1993
21. Kuhn J, Rizzo J, Eckardt J, et al: Phase I bioavailability study of oral topotecan. Proc Am Soc Clin Oncol 14:474, 1995 (abstr 1538)
22. Stewart CF, Zamboni WC, Crom WR, et al: Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. Cancer Chemother Pharmacol 40:259-265, 1997
23. Rivory LP, Haaz M-C, Canal P, et al: Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolitesin patients enrolled in phase I/II trials. Clin Cancer Res 3:1261-1266, 1997
24. Canal P, Gay C, Dezeuze A, et al: Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 14:2688-2695, 1996
25. Sasaki Y, Yoshida Y, Sudoh K, et al: Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn J Cancer Res 86:111-116, 1995
26. Haaz MC, Rivory LP, Riché C, et al: Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P-450 3A and drug interactions. Cancer Res 58:468-472, 1998